INTRODUCTION/ BACKGROUND: We evaluated the characteristics of a cohort of patients with myelodysplastic syndrome (MDS) related to therapy (t-MDS) to create a prognostic model. PATIENTS AND METHODS: We identified 281 patients with MDS who had received previous chemotherapy and/or radiotherapy for previous malignancy. Potential prognostic factors were determined using univariate and multivariate analyses. RESULTS: Multivariate Cox regression analysis identified 7 factors that independently predicted short survival in t-MDS: age ≥ 65 years (hazard ratio [HR], 1.63), Eastern Cooperative Oncology Group performance status 2-4 (HR, 1.86), poor cytogenetics (-7 and/or complex; HR, 2.47), World Health Organization MDS subtype (RARs or RAEB-1/2; HR, 1.92), hemoglobin (< 11 g/dL; HR, 2.24), platelets (< 50 × 10(9)/dL; HR, 2.01), and transfusion dependency (HR, 1.59). These risk factors were used to create a prognostic model that segregated patients into 3 groups with distinct median overall survival: good (0-2 risk factors; 34 months), intermediate (3-4 risk factors; 12 months), and poor (5-7 risk factors; 5 months) (P < .001) and 1-year leukemia-free survival (96%, 84%, and 72%, respectively, P = .003). This model also identified distinct survival groups according to t-MDS therapy. CONCLUSION: In summary, we devised a prognostic model specifically for patients with t-MDS that predicted overall survival and leukemia-free survival. This model might facilitate the development of risk-adapted therapeutic strategies.
INTRODUCTION/ BACKGROUND: We evaluated the characteristics of a cohort of patients with myelodysplastic syndrome (MDS) related to therapy (t-MDS) to create a prognostic model. PATIENTS AND METHODS: We identified 281 patients with MDS who had received previous chemotherapy and/or radiotherapy for previous malignancy. Potential prognostic factors were determined using univariate and multivariate analyses. RESULTS: Multivariate Cox regression analysis identified 7 factors that independently predicted short survival in t-MDS: age ≥ 65 years (hazard ratio [HR], 1.63), Eastern Cooperative Oncology Group performance status 2-4 (HR, 1.86), poor cytogenetics (-7 and/or complex; HR, 2.47), World Health Organization MDS subtype (RARs or RAEB-1/2; HR, 1.92), hemoglobin (< 11 g/dL; HR, 2.24), platelets (< 50 × 10(9)/dL; HR, 2.01), and transfusion dependency (HR, 1.59). These risk factors were used to create a prognostic model that segregated patients into 3 groups with distinct median overall survival: good (0-2 risk factors; 34 months), intermediate (3-4 risk factors; 12 months), and poor (5-7 risk factors; 5 months) (P < .001) and 1-year leukemia-free survival (96%, 84%, and 72%, respectively, P = .003). This model also identified distinct survival groups according to t-MDS therapy. CONCLUSION: In summary, we devised a prognostic model specifically for patients with t-MDS that predicted overall survival and leukemia-free survival. This model might facilitate the development of risk-adapted therapeutic strategies.
Authors: Zeba N Singh; Dezheng Huo; John Anastasi; Sonali M Smith; Theodore Karrison; Michelle M Le Beau; Richard A Larson; James W Vardiman Journal: Am J Clin Pathol Date: 2007-02 Impact factor: 2.493
Authors: Smita Bhatia; Mark D Krailo; Zhengjia Chen; Laura Burden; Frederic B Askin; Paul S Dickman; Holcombe E Grier; Michael P Link; Paul A Meyers; Elizabeth J Perlman; Aaron R Rausen; Leslie L Robison; Teresa J Vietti; James S Miser Journal: Blood Date: 2006-09-19 Impact factor: 22.113
Authors: A Iurlo; C Mecucci; A Van Orshoven; J L Michaux; M Boogaerts; L Noens; A Bosly; A Louwagie; H Van Den Berghe Journal: Cancer Genet Cytogenet Date: 1989-12
Authors: M Lessard; C Hélias; S Struski; N Perrusson; F Uettwiller; M-J Mozziconacci; M Lafage-Pochitaloff; N Dastugue; C Terré; F Brizard; P Cornillet-Lefebvre; F Mugneret; C Barin; A Herry; I Luquet; F Desangles; L Michaux; C Verellen-Dumoulin; C Perrot; J Van den Akker; J Lespinasse; V Eclache; R Berger Journal: Cancer Genet Cytogenet Date: 2007-07-01
Authors: Gail J Roboz; John M Bennett; Morton Coleman; Ellen K Ritchie; Richard R Furman; Adrianna Rossi; Komal Jhaveri; Eric J Feldman; John P Leonard Journal: Leuk Res Date: 2007-05-01 Impact factor: 3.156
Authors: H M Kantarjian; M J Keating; R S Walters; T L Smith; A Cork; K B McCredie; E J Freireich Journal: J Clin Oncol Date: 1986-12 Impact factor: 44.544
Authors: M M Le Beau; K S Albain; R A Larson; J W Vardiman; E M Davis; R R Blough; H M Golomb; J D Rowley Journal: J Clin Oncol Date: 1986-03 Impact factor: 44.544
Authors: F P Tambaro; G Garcia-Manero; S M O'Brien; S H Faderl; A Ferrajoli; J A Burger; S Pierce; X Wang; K-A Do; H M Kantarjian; M J Keating; W G Wierda Journal: Leukemia Date: 2015-08-20 Impact factor: 11.528
Authors: N Gunnarsson; M Höglund; L Stenke; S Wållberg-Jonsson; F Sandin; M Björkholm; A Dreimane; M Lambe; B Markevärn; U Olsson-Strömberg; H Wadenvik; J Richter; A Själander Journal: Leukemia Date: 2016-03-08 Impact factor: 11.528
Authors: A M Zeidan; N Al Ali; J Barnard; E Padron; J E Lancet; M A Sekeres; D P Steensma; A DeZern; G Roboz; E Jabbour; G Garcia-Manero; A List; R Komrokji Journal: Leukemia Date: 2017-01-23 Impact factor: 11.528